Search

Displaying results 1871 - 1880 of 8517 in total
  1. Drug

    Tenofovir

    go.drugbank.com/drugs/DB14126
    Investigational

    [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. … [A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order

  2. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

  3. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    It is often used as first-line therapy for OAB.[A185990] … [A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and

  4. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of

  5. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030, A241040] Narsoplimab (OMS721), a human IgG4λ anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy

  6. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476]. … Proxibarbal is a derivative of barbiturates, which has been used to treat migraines.

  7. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

  8. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … [L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961.

  9. Drug

    Phendimetrazine

    go.drugbank.com/drugs/DB01579
    ApprovedIllicit

    Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.

  10. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.